This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Wyeth to Provide More Data on Drug

Wyeth (WYE) said Tuesday that the Food and Drug Administration wants more information about an experimental drug to prevent osteoporosis before it will grant full clearance for the treatment.

The announcement of the FDA's conditional approval wasn't a surprise because Wyeth had predicted such a delay last week. Known scientifically as bazedoxifene, the drug will be sold under the brand name Viviant.

The FDA's decision "is in line with our expectations," said Dr. Gary Stiles, executive vice president and chief medical officer of Wyeth's human-drug business. "We will work closely with the FDA ... and are moving forward with plans to seek an additional indication for the treatment of postmenopausal osteoporosis later this year."

Wyeth must achieve several goals to secure final approval. The FDA has to receive and analyze additional safety and efficacy data from a recently completed clinical trial. The agency will be looking at bone-fracture data, and Wyeth said last week the review could take six months.

The FDA also must sign off on manufacturing and testing facilities for the drug at Wyeth's plant in Puerto Rico. The plant has been under FDA scrutiny since May 2006 for manufacturing problems. Until the FDA approves Wyeth's plan to fix the shortcomings, the company can't make new drugs there.

"We believe the situation ... will be resolved without affecting the timing of new product launches," Wyeth said. The stock closed at $55.53, down 20 cents.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.04 1.50%
FB $117.96 -0.51%
GOOG $695.37 -0.41%
TSLA $236.13 -2.30%
YHOO $36.09 -1.20%


Chart of I:DJI
DOW 17,741.68 -149.48 -0.84%
S&P 500 2,061.50 -19.93 -0.96%
NASDAQ 4,767.6290 -49.9650 -1.04%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs